Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

NEW YORK, Jan. 24, 2024 -- Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and...

Related Keywords

Andrewj Barwicki ,Alzheimers Dement ,Christopheru Missling ,Company On Twitter ,Michaelj Fox Foundation For Parkinson Research ,Nasdaq ,Muscarinic Receptor Agonist In Development ,Clinical Pharmacology In Drug Development ,Globenewswire Inc ,Anavex Life Sciences Corp ,Facebook ,Linkedin ,Instagram ,Company Nasdaq ,Research Business Development ,Life Sciences ,Clinical Pharmacology ,Drug Development ,Population Based Characterization ,Food Effect ,Receptor Agonist ,Frontotemporal Dementia ,Karuna Therapeutics ,Chief Executive Officer ,Annual Report ,Further Information ,Based Characterization ,Clin Pharmacol Drug ,Therapeutic Efficacy ,Animal Models ,